Vicarious Surgical’s Beta 2 surgical robotic system. | Credit score: Vicarous Surgical
Vicarious Surgical (NYSE:RBOT) introduced that the NYSE has commenced the method of delisting its inventory.
The Waltham, Massachusetts–primarily based surgical robotic developer obtained a discover from the inventory change yesterday, March 3, 2026. Because of the NYSE motion, the corporate’s inventory was suspended after market shut.
Shares of RBOT are at present buying and selling at $1.92 apiece forward of the opening of the NYSE market at the moment.
Vicarious mentioned that the NYSE decided that its inventory fell under the continued itemizing customary. It requires firms to keep up a median international market capitalization over a consecutive 30-day buying and selling interval of at the least $15 million.
The corporate should make an enchantment inside 10 enterprise days from receipt of the discover. It mentioned it at present has a possible enchantment underneath analysis. In the meantime, the corporate obtained approval to have its inventory quoted on the OTCID market tier operated by the OTC Markets Group. It expects frequent inventory to start citation on that market on the open of enterprise at the moment, March 4, 2026. The corporate intends to proceed buying and selling underneath the “RBOT” ticker.
This isn’t the primary time the corporate has confronted delisting, having fallen below NYSE standards in 2023. It then conducted a reverse stock split halfway by 2024.
The newest on Vicarious Surgical’s efforts
Potential delisting comes at an fascinating time for Vicarious, which has been advancing a surgical robotic platform for a while, however has hit varied snags alongside the way in which.
Vicarious designed its robotic to extend the effectivity of surgical procedures. The corporate beforehand set its sights on first-in-human trials halfway by 2025, however delayed the robot’s timeline back in November 2023. Then, in March 2024, the company outlined plans to have its “V1.0” system prepared for an FDA submission by early to mid-fiscal 2026.
In late 2024, the company said it deliberate for a year-end cadaver lab for V1.0, adopted by efforts towards verification, validation, and optimization of the system forward of formal scientific testing. In Might 2025, Vicarious announced a new hospital collaboration, transferring nearer to bringing its surgical robotic expertise to sufferers. However, in August, the corporate mentioned it will hold off on clinical trial initiation to further develop its robot. At the moment, the corporate earmarked the top of 2026 for its design freeze.
In the beginning of this yr, the corporate efficiently completed an in-vivo porcine lab for the robot. It mentioned the lab reinforces its progress towards a system design freeze earmarked for the top of 2026.
The submit Vicarious Surgical faces NYSE delisting once more appeared first on The Robotic Report.
